title: Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis.
abstract: The authors describe a 39-year-old woman treated with fingolimod for relapsing-remitting multiple sclerosis for 2 years who then developed a bilateral conjunctival mucosa-associated lymphoid tissue lymphoma. Fingolimod treatment for multiple sclerosis has been associated with lymphoma in 3 previously reported cases. This is the first case of ocular adnexal lymphoma presumed to be due to fingolimod. Given that ophthalmologists regularly monitor many patients on fingolimod for fingolimod-associated macular edema and ophthalmic manifestations of multiple sclerosis, the authors hope to alert physicians of the possibility of ocular adnexal lymphoma in these patients.
authors.affiliation: Department of Ophthalmology and Visual Science, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, U.S.A.
authors.forename: Karen L
authors.initials: KL
authors.lastname: Christopher
authors.forename: Victor M
authors.initials: VM
authors.lastname: Elner
authors.forename: Hakan
authors.initials: H
authors.lastname: Demirci
mesh_terms: D000328:Adult; D001706:Biopsy; D003228:Conjunctiva / Q000473:pathology*; D003230:Conjunctival Neoplasms / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D018442:Lymphoma, B-Cell, Marginal Zone / Q000139:chemically induced* / Q000175:diagnosis; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D000068876:Fingolimod Hydrochloride